531 results on '"Casanova, Ciro"'
Search Results
2. Triple Therapy and Clinical Control in B+ COPD Patients: A Pragmatic, Prospective, Randomized Trial
3. Association between occupational exposure and chronic obstructive pulmonary disease and respiratory symptoms in the Spanish population
4. Impact of Applying the Global Lung Initiative Criteria for Airway Obstruction in GOLD Defined COPD Cohorts: The BODE and CHAIN Experience
5. Tobacco Patterns and Risk of Chronic Obstructive Pulmonary Disease: Results From a Cross-Sectional Study
6. Trends of COPD in Spain: Changes Between Cross Sectional Surveys 1997, 2007 and 2017
7. Dissociation between physical capacity and daily physical activity in COPD patients. A population-based approach
8. The 7 Cardinal Sins of COPD in Spain
9. [Translated article] Spanish COPD Guideline (GesEPOC) Update: Comorbidities, Self-Management and Palliative Care
10. [Translated article] Spanish COPD Guidelines (GesEPOC 2021): Non-pharmacological Treatment Update
11. Actualización de la Guía Española de la EPOC (GesEPOC): comorbilidades, automanejo y cuidados paliativos
12. Actualización 2021 de la Guía Española de la EPOC (GesEPOC). Tratamiento no farmacológico
13. Associations between serum mitokine levels and outcomes in stable COPD: an observational prospective study
14. Determinants of blood eosinophil levels in the general population and patients with COPD: a population-based, epidemiological study
15. Comorbidities and mortality risk in adults younger than 50 years of age with chronic obstructive pulmonary disease
16. [Translated article] Spanish COPD Guidelines (GesEPOC) 2021 Update. Diagnosis and Treatment of COPD Exacerbation Syndrome
17. Actualización 2021 de la guía española de la EPOC (GesEPOC). Diagnóstico y tratamiento del síndrome de agudización de la EPOC
18. [Translated article] Spanish COPD guidelines (GesEPOC) 2021: Updated pharmacological treatment of stable COPD
19. Actualización 2021 de la Guía Española de la EPOC (GesEPOC). Tratamiento farmacológico de la EPOC estable
20. Oxidative Damage and Telomere Length as Markers of Lung Cancer Development among Chronic Obstructive Pulmonary Disease (COPD) Smokers
21. Home noninvasive ventilation in severe COPD: in whom does it work and how?
22. Psoas Muscle Density Evaluated by Chest CT and Long-Term Mortality in COPD Patients
23. High parathyroid hormone predicts exacerbations in COPD patients with hypovitaminosis D
24. Prevalence and Determinants of COPD in Spain: EPISCAN II
25. Sex differences between women and men with COPD: A new analysis of the 3CIA study
26. 10 Years After EPISCAN: A New Study on the Prevalence of COPD in Spain—A Summary of the EPISCAN II Protocol
27. Nuevo estudio sobre la prevalencia de la EPOC en España: resumen del protocolo EPISCAN II, 10 años después de EPISCAN
28. Characteristics of COPD Patients Managed in Respiratory Medicine Departments in Spain, According to GOLD Groups and GesEPOC Clinical Phenotypes
29. Características de los pacientes con EPOC tratados en neumología en España según grupos GOLD y fenotipos clínicos GesEPOC
30. Circulating miR-206 and miR-1246 as Markers in the Early Diagnosis of Lung Cancer in Patients with Chronic Obstructive Pulmonary Disease
31. Temporal transitions in COPD severity stages within the GOLD 2017 classification system
32. Shorter telomeres in non-smoking patients with airflow limitation
33. Expert Statement on the Single-Agent Use of Inhaled Bronchodilator in the Treatment of Stable Mild-Moderate Chronic Obstructive Pulmonary Disease
34. Documento de expertos del uso de broncodilatadores inhalados en monoterapia en el tratamiento de la EPOC estable leve-moderada
35. The variability of respiratory symptoms and associated factors in COPD
36. Consensus on the Asthma–COPD Overlap (ACO) Between the Spanish COPD Guidelines (GesEPOC) and the Spanish Guidelines on the Management of Asthma (GEMA)
37. Consenso sobre el solapamiento de asma y EPOC (ACO) entre la Guía española de la EPOC (GesEPOC) y la Guía Española para el Manejo del Asma (GEMA)
38. Spanish COPD Guidelines (GesEPOC) 2017. Pharmacological Treatment of Stable Chronic Obstructive Pulmonary Disease
39. Guía española de la enfermedad pulmonar obstructiva crónica (GesEPOC) 2017. Tratamiento farmacológico en fase estable
40. Plasma metabolomics and clinical predictors of survival differences in COPD patients
41. Respiratory symptoms and their determinants in the general Spanish population: changes over 20 years
42. Circulating levels of mitochondrial oxidative stress-related peptides MOTS-c and Romo1 in stable COPD: A cross-sectional study
43. Prevalence of reduced lung diffusing capacity and CT scan findings in smokers without airflow limitation: a population-based study
44. A longitudinal and multidesign epidemiological study to analyze the effect of the volcanic eruption of Tajogaite volcano (La Palma, Canary Islands). The ASHES study protocol
45. Identification of COPD Patients at High Risk for Lung Cancer Mortality Using the COPD-LUCSS-DLCO
46. Prevalence of reduced lung diffusing capacity and CT scan findings in smokers without airflow limitation : a population-based study
47. “Correct Use of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease”: A Consensus Document
48. Documento de consenso «Uso adecuado de los corticoides inhalados en la enfermedad pulmonar obstructiva crónica»
49. Analysis of Exposure and Respiratory Health Effects of Volcanic Eruption in the Canary Islands (ASHES). A SEPAR Study
50. Unravelling young COPD and pre-COPD in the general population
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.